Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAd-p53 Gene Therapy in Advanced Oral and Maxillofacial Malignant Tumors
NCT00902083Phase 4Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- Jun 2009
- Primary completion
- Jul 2012
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rAdp53 in oral and maxillofacial cancer (4 arms), sponsored by Shenzhen SiBiono GeneTech. Primary endpoints: Target Lesion Complete Response Rate, Overall Target Lesion Response Rate and 2 more. Status: unknown.
02
Drugs
rAdp53
03
Conditions
oral and maxillofacial cancer
Beyond the preview
Go deeper on NCT00902083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902083.